TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02652169
Drug: PRF mixed with amikacin and teicoplanin
Normalized name: teicoplanin
DrugBank: Teicoplanin (DB06149)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PRF, mixed with amikacin and teicoplanin is applied to the chronic ulcer
Study: NCT02652169
Drug: PRF mixed with PHMB plus Macrogolol
Normalized name: Humalog Mix
Approvals — FDA: no, EMA: no, PMDA: no
Description: PRF, mixed with Lavasorb is applied to the chronic ulcer
Study: NCT00457652
Drug: Rosuvastatin
Normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 7 day treatment rosuvastatin 20mg
Study: NCT05410678
Drug: Renal stent
Normalized name: Sus scrofa renal pelvis preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: renal stent implantation in ectatic/aneurysmatic coronary arteries
Study: NCT01805895
Drug: Minocycline
Normalized name: Minocycline
DrugBank: Minocycline (DB01017)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: This arm will receive a total of 5 doses of minocycline. Dose 1 will be 400mg IV within 12-hours of onset of symptoms. Dose 2 will be 400mg oral, given daily on days 2-5 . Each dose is 24 hours apart.
Study: NCT03490903
Drug: Fentanyl Injection
Normalized name: fentanyl Injection
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Fentanyl is commonly administered to treat pain during invasive procedures such as coronary angiography. Intravenous fentanyl injection dosages are determined by the physician operator, and administered by the circulating nurse.
Study: NCT04197739
Drug: Amikacin
Normalized name: amikacin
DrugBank: Amikacin (DB00479)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Patients in the intervention arm will receive a fixed, single daily dose of amikacin, 500 mg, a day.~Patients in the Comparator arm will receive a weight adjusted loading dose of amikacin (15 mg/kg adjusted body weight) and continue in adjusted intervals according to the Barnes Jewish Hospital nomogram
Study: NCT00004242
Drug: fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00597818
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo capsules for oral administration
Study: NCT00597818
Drug: Non-steroidal anti-inflammatory drug
Normalized name: Surpass Anti-Inflammatory
Approvals — FDA: no, EMA: no, PMDA: no
Description: Any marketed non-steroidal anti-inflammatory drug used by the participants as standard care.
Study: NCT02751268
Drug: Normal Saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bilateral infraorbital and infratrochlear nerve block before general anesthesia with normal saline
Study: NCT03090139
Drug: Anti-TNF Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-TNF therapy.
Study: NCT00440440
Drug: Testosterone gel
Normalized name: Androgel 1.62% Metered Dose Pump Testosterone Gel
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Testosterone gel to be applied daily, starting does 5g.
Study: NCT00440440
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo gel apply daily
Study: NCT00329173
Drug: Rosuvastatin
Normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02910050
Drug: Aromatase Inhibitor
Normalized name: Aromatase inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: participants will receive any kind of aromatase inhibitor which has not been received before (steroidal AI change to nonsteroidal AI and vice versa), Letrozole 2.5mg once a day orally, Anastrozole 1mg once a day orally, Exemestane 25mg once a day orally
Study: NCT02943239
Drug: REGN2477
Approvals — FDA: no, EMA: no, PMDA: no
Description: REGN2477
Study: NCT03764527
Drug: Artemether-lumefantrine
Normalized name: artemether-lumefantrine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two doses a day for 3 days, under supervision
Study: NCT00939159
Drug: LBH589
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg capsules by mouth 3 times a week for 3 weeks in a 28-day cycle.
Study: NCT02184364
Drug: Low dose of Klimadynon®
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02184364
Drug: High dose of Klimadynon®
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02184364
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00662818
Drug: Acetaminophen/Paracetamol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetaminophen/Paracetamol (500 mg X 2 dosage units)
Study: NCT00662818
Drug: Placebo to Acetaminophen/Paracetamol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo to acetaminophen/paracetamol (500 mg X 2 dosage units)
Study: NCT04647552
Drug: Drug Steroid
Approvals — FDA: no, EMA: no, PMDA: no
Description: hydrocortisone injection
Study: NCT00659178
Drug: SB-485232 (interleukin 18), pegylated liposomal doxorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: SB-485232 (interleukin 18), pegylated liposomal doxorubicin
Study: NCT00388791
Drug: Systane Free
Normalized name: Systane Free
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02974868
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT01755507
Drug: norUDCA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparison of different dosages of norUDCA acid administered orally.
Study: NCT01755507
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03286101
Drug: Vehicle
Normalized name: Drug vehicle
Approvals — FDA: no, EMA: no, PMDA: no
Description: The intervention is composed of a single application of the vehicle control.
Study: NCT00672945
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02389959
Drug: Placebo (Saline)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4mL of saline will be mixed by the Stanford Hospital Pharmacy as a control
Study: NCT02751320
Drug: 1150ppm F
Normalized name: F
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants were assigned with 1.5±0.1g twice daily dentifrice for one timed minute.
Study: NCT03901482
Drug: Placebos
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo for STS101
Study: NCT01382277
Drug: Rosuvastatin
Normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Rosuvastatin 20 mg per day for 76 weeks
Study: NCT00258557
Drug: LPV/RTV
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400/100 mg twice daily or 800/200 mg daily depending on the country for max. 192 weeks
Study: NCT03148444
Drug: cefalexin 500 mg qid or roxithromycin 150 mg bid
Normalized name: roxithromycin 150 MG
DrugBank: Roxithromycin (DB00778)
Approvals — FDA: no, EMA: no, PMDA: no
Description: antibiotics treatment for five days following implantation of cardiac device
Study: NCT02794922
Drug: Neurovit Forte
Normalized name: Erythroped Forte
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00409539
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, 2 week duration.
Study: NCT02204501
Drug: Vapendavir 264 mg BID
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twelve subjects (6 male and 6 female) will receive 264 mg vapendavir (achieved with two 132 mg vapendavir capsules) BID daily as divided dose given in the morning and evening 12 hours apart for seven days.
Study: NCT02204501
Drug: Vapendavir 528 mg QD
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twelve subjects (6 male and 6 female) will receive 528 mg vapendavir (achieved with four 132 mg vapendavir capsules) QD in the morning for seven days
Study: NCT00409539
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Taken for the 8 week duration, in parallel with alternative arms (doses of 20, 40, 80 or 120mg SMP-986).
Study: NCT00531453
Drug: bortezomib, dexamethasone, thalidomide, and cyclophosphamide
Approvals — FDA: no, EMA: no, PMDA: no
Description: VELCADE (bortezomib) twice weekly for 4 cycles (4 doses per cycle), prior to high-dose chemotherapy(HDT)and stem cell transplantation(SCT). Subjects will receive VELCADE 1.3 mg/m2 as an intravenous (i.v.) bolus injection on Days 1,4,8, and 11, followed by a 10 day rest period (Days 12 to 21).~Dexamethasone 40 mg/day will be given by mouth (p.o.) on Days 1-4 and Days 9-12 in each of 4 cycles.~Thalidomide will be given by mouth (p.o.) every day, starting on Day 1 of Cycle 1 (e.g., the same day of the first dose of VELCADE) and continuing until Day 21 of Cycle 4 at a dose of 100 mg/day (bedtime).~Cyclophosphamide will be given as an intravenous (i.v.) dose of 400 mg/m2 on Day 1 and Day 8 of each 3-week cycle, for a total of 4 cycles.
Study: NCT00305162
Drug: Placebo bolus & placebo infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo bolus (30 mcg/kg) \& placebo infusion (4 mcg/kg/min) administered from randomization for at least 2 hours, or until the end of the PCI, whichever is longer with the option to extend up to 4 hours maximum (per investigator discretion)
Study: NCT00305162
Drug: Placebo capsules - end of infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo capsules given at the end of infusion to mimic 600mg clopidogrel dosing
Study: NCT00003509
Drug: Antineoplaston therapy (Atengenal + Astugenal)
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients with Stage IV Melanoma will receive Antineoplaston therapy (Atengenal + Astugenal).~The daily doses of A10 and AS2-1 are divided into six infusions, which are given at 4-hourly intervals. Each infusion starts with infusion of A10 and is immediately followed by infusion of AS2-1.
Study: NCT04447820
Drug: K-877-ER (Dose A)
Normalized name: K+ 8 MEQ Extended Release Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose A Oral Administration
Study: NCT04447820
Drug: K-877-ER (Dose B)
Normalized name: K+ 8 MEQ Extended Release Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose B Oral Administration
Study: NCT04447820
Drug: K-877-IR
Normalized name: K
Approvals — FDA: no, EMA: no, PMDA: no
Description: K-877-IR Oral Administration
Study: NCT00305162
Drug: Placebo capsules - as soon as possible after randomization
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo capsules given as soon as possible after randomization to mimic 600mg clopidogrel dosing
Study: NCT02400801
Drug: ethinylestradiol + dienogest
Normalized name: Dienogest
DrugBank: Dienogest (DB09123)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: oral oestroprogestogen
Study: NCT02019667
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00621790
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo
Study: NCT01270074
Drug: Azithromycin
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: azithromycin will be given as a liquid preparation at a dose of 10 mg/kg three times per week from three months of age until three years of age
Study: NCT02101385
Drug: Genomically Directed Monotherapy
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants randomized to Experimental Arm A will receive an FDA approved drug at standard dose for four cycles (12-16 weeks total duration, depending on cycle length). The CGTB will assign therapy to each participant individually based on biomarkers/pathways identified by DNA sequencing:
Study: NCT04224337
Drug: Durvalumab + doxorubicin + ifosfamide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Durvalumab: 1500mg via IV infusion on day 1 Q3W for 4 cycles followed by durvalumab monotherapy 1500mg via IV infusion Q4W for up to a maximum 12 months Doxorubicin 20mg/m2 via IV infusion on day 1 to day 3 Q3W (up to 4 cycles) Ifosfamide: 1.5g/m2 (with mesna) via IV infusion on day 2 to day 4 Q3W (up to 4cycles)
Study: NCT00157339
Drug: Human Insulin Inhalation Powder
Normalized name: insulin, regular, human Inhalation Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: patient specific dose, inhaled, before meals, 12 months
Study: NCT01746862
Drug: Saizen®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects in the Saizen test group will receive Saizen (recombinant-human growth hormone \[r-hGH\]) subcutaneously 6 days per week at a weight based dose of 0.067 milligram per kilogram of body weight per day (mg/kg/day) for 12 months.
Study: NCT01746862
Drug: Saizen®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects in the Saizen control group will receive no treatment for the first 6 months and thereafter will receive Saizen (r-hGH) subcutaneously 6 days per week at a weight based dose of 0.067 mg/kg/day for the next 6 months.
Study: NCT06729658
Drug: Madopar
Normalized name: Madopar
Approvals — FDA: no, EMA: no, PMDA: no
Description: Experimental group participants will receive Madopar 125mg for 6 days.
Study: NCT06729658
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group participants will receive placebo for 6 days.
Study: NCT00427310
Drug: sodium heparin
Normalized name: Heparin Sodium
DrugBank: Heparin (DB01109)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT04666623
Drug: placebo nasal spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: unlabeled nasal injectors, each device will deliver 28mg of placebo in a 200 μL solution, so in order to achieve the 56mg dose two devices will be required. On each dosing day during the trial, participants will self-administer at 2 time points 1 spray of the nasal spray into each nostril. Each administration will be separated by 5 minutes. The participants will receive the intervention twice weekly for 4 consecutive weeks.
Study: NCT01964027
Drug: second line chemoregime for advanced gastric cancer
Normalized name: gastric mucins
Approvals — FDA: no, EMA: no, PMDA: no
Description: Irinotecan(Camptosar)150mg /m2 d1,（intravenous infusion of 30-90 minutes) + epirubicin(Pharmorubicin) 50mg/m2 (total dose does not exceed 700mg/m2) every 21days for 1 treatment \* 6 cycles as the second line chemoregime for advanced gastric cancer
Study: NCT02253394
Drug: Ambrisentan plus Spironolactone
Normalized name: Ambrisentan
DrugBank: Ambrisentan (DB06403)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Cardiopulmonary fitness
Study: NCT02070939
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will receive single doses of PF-06260414 matching placebo (solution) in a dose escalation format
Study: NCT02070939
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will receive PF-06260414 matching placebo doses (solution) of 3, 10, 30, 100mg BID and 60 mg QD for 14 days
Study: NCT02070939
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Japanese subjects may receive PF-06260414 matching placebo doses (solution) twice daily for 14 days
Study: NCT02314780
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02413853
Drug: Leucovorin Calcium
Normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT02413853
Drug: Fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT02115984
Drug: Panagen
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02115984
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04390646
Drug: 0.9% NaCl
Normalized name: Trace Metals Additive in 0.9% NaCl
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug administered by a subcutaneous pump
Study: NCT00225017
Drug: current antiretroviral regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continue current antiretroviral regimen for 24 weeks, single or RTV-boosted PI plus \> 2 NRTIs
Study: NCT01231009
Drug: Corticosteroids
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous Dexamethasone, 8mg three times per day tapering down for 7 days Per os dexamethasone, 2mg per day tapering down for 7 days
Study: NCT01909804
Drug: SOF
Normalized name: Kasof
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg tablet administered orally once daily
Study: NCT05558397
Drug: Control Group (Oral morphine)
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral administration of morphine, pregabalin or duloxetin
Study: NCT04394208
Drug: Silymarin
Normalized name: silymarin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Silymarin Oral at a dose of 420 mg/day in 3 divided doses.
Study: NCT04394208
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo comparator
Study: NCT03257943
Drug: SKLICE (ivermectin) Lotion, 0.5%
Approvals — FDA: no, EMA: no, PMDA: no
Description: SKLICE (ivermectin) Lotion, 0.5% (Arbor Pharmaceuticals, LLC)
Study: NCT03257943
Drug: Vehicle of the Test product
Normalized name: The Magic Bullet Rectal Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vehicle for Ivermectin Lotion, 0.5% (Taro Pharmaceuticals Inc.)
Study: NCT01769768
Drug: LDE225
Approvals — FDA: no, EMA: no, PMDA: no
Description: LDE225 800 mg once daily dosing will begin on Cycle 1 Day 1 of a 28-day cycle.Treatment with LDE225 for both groups will continue until the patient experiences unacceptable toxicity that precludes further treatment, disease progression, withdrawal of consent and/or at the discretion of the investigator.
Study: NCT04007328
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline manufactured to mimic methylprednisolone vial
Study: NCT01769768
Drug: Wafarin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mg single dose of warfarin (oral tablet) will be given to patients.
Study: NCT01579279
Drug: ABT-652 6 mg
Normalized name: ABT-925
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 mg capsules
Study: NCT01579279
Drug: ABT-652 12 mg
Normalized name: ABT-925
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12 mg capsules
Study: NCT01579279
Drug: ABT-652 12 mg - 18 mg
Normalized name: ABT-925
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12 mg - 18 mg capsules
Study: NCT01579279
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo capsules
Study: NCT01994759
Drug: Glucocorticosteroid injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultra sound guided injection af 1 ml og Glucocorticosteroid (methylprednisolone 40 mg) and 1 ml of lidocaine 5mg/ml from the medial side profound to the thickened part of the fascia plantaris.~Glucocorticosteroid injections are given every month until the aponeurosis thickness is less than 4 mm as determined by ultrasonography (max 3 injections).
Study: NCT01177800
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo matched to infliximab given at Weeks 10, 12 and 16 in Infliximab arm and at Weeks 0, 2 and 6 in Placebo arm
Study: NCT01542138
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Humectant placebo cream
Study: NCT04030741
Drug: Meronem and flagyl
Approvals — FDA: no, EMA: no, PMDA: no
Description: meronem and flagy
Study: NCT00441285
Drug: ABZ Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: - Placebo (of Albendazole ) 7.5 mg / kg / d in Arm I and II for 10 days.
Study: NCT00441285
Drug: PZQ Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: - Placebo (of Praziquantel) 50 mg / kg / d in Arm II and III for 10 days.
Study: NCT01533116
Drug: BIA 9-1067
Normalized name: Oatmeal 10 mg in 1 mL TOPICAL CREAM [BIA Eczema Relief]
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01097707
Drug: LY500307
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally, daily for 24 weeks
Study: NCT01097707
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally, daily for 24 weeks
Study: NCT01533116
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01533116
Drug: levodopa/carbidopa
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01533116
Drug: levodopa/benserazide
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00911937
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo sham 4mg and 8 mg tables taken daily.
Study: NCT02797431
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: IM administration of Placebo (SC administration for patients with INR\>2.5 or platelet count \< 35,000
Study: NCT00168051
Drug: Advante
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02999893
Drug: APR-246
Normalized name: PrameGel Reformulated Apr 2012
Approvals — FDA: no, EMA: no, PMDA: no
Description: APR-246 (also known as PRIMA-1MET), a first-in-class agent targeting mutant p53 resulting in re-expression of wild-type p53 activity.
Study: NCT00011752
Drug: FCWAY
Normalized name: Fenclonine
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02232607
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01316718
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2g oral granules, once a day for 1 week, then 2g oral granules, twice a day for 11 weeks
Study: NCT01687218
Drug: Oral FTC/TDF (Daily Emtricitabine/Tenofovir Disoproxil fumarate Tablet)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01687218
Drug: Rectal Daily TFV RG 1% gel (Rectally applied Tenofovir Reduced Glycerin 1% Gel)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01687218
Drug: Rectal RAI-associated TFV RG 1% gel (Receptive Anal Intercourse Associated rectally applied Tenofovir Reduced Glycerin 1% Gel)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04083560
Drug: Vit B12
Normalized name: vit B12/pyridoxine/thiamine ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin B12 250mcg
Study: NCT00502567
Drug: AZD2171
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral tablet once daily
Study: NCT00502567
Drug: FOLFOX
Approvals — FDA: no, EMA: no, PMDA: no
Description: intravenous infusion
Study: NCT02393027
Drug: [18F] LBT-999 PET
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04357444
Drug: 1: ILT101
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous injections, once-daily administration for 10 consecutive days.
Study: NCT04357444
Drug: 2: Placebo Comparator
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo in Subcutaneous route
Study: NCT02076620
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Doxorubicin will be administered as a 15 minutes i.v. infusion on day 1 of each 3-week cycle prior L19TNFα administration.
Study: NCT01659853
Drug: CD07805/47 gel 0.5%/CD07805/47 Vehicle
Approvals — FDA: no, EMA: no, PMDA: no
Description: To maintain masking, CD07805/47 gel 0.5% will be administered along with CD07805/47 gel vehicle.~During each treatment period (baseline to Day 15):~CD07805/47 gel 0.5%, topical, once daily and CD07805/47 gel vehicle, topical, once daily
Study: NCT04938700
Drug: probiotics
Normalized name: probiotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotics as granules can be used for infants and adolescents
Study: NCT04938700
Drug: conventional medical treatment
Normalized name: zinc pyrithione Medicated Shampoo [Head & Shoulders Damage Treatment]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment for allergic diseases includes anti-allergic drugs, nasal spray hormones, inhaled hormones, external hormones, etc